Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Share-based Compensation (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Share-based Compensation for 5 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 14.49% year-over-year to $1.5 million, compared with a TTM value of $5.0 million through Dec 2025, down 40.32%, and an annual FY2025 reading of $5.0 million, down 40.32% over the prior year.
  • Share-based Compensation was $1.5 million for Q4 2025 at Aligos Therapeutics, down from $1.5 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $6.2 million in Q2 2021 and bottomed at $959000.0 in Q1 2025.
  • Average Share-based Compensation over 5 years is $2.9 million, with a median of $3.2 million recorded in 2023.
  • The sharpest move saw Share-based Compensation fell 3.05% in 2022, then crashed 63.78% in 2025.
  • Year by year, Share-based Compensation stood at $3.7 million in 2021, then dropped by 6.44% to $3.4 million in 2022, then decreased by 24.39% to $2.6 million in 2023, then plummeted by 33.99% to $1.7 million in 2024, then decreased by 14.49% to $1.5 million in 2025.
  • Business Quant data shows Share-based Compensation for ALGS at $1.5 million in Q4 2025, $1.5 million in Q3 2025, and $1.2 million in Q2 2025.